Table 4 Susceptibility of pathogens in different infections for antibiotics commonly used in mono- or combination therapy
Antibiotic agent | SBP | BSI | UTI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
S | R | S | R | S | R | |||||||
n | % | n | % | n | % | n | % | n | % | n | % | |
Ampicillin/sulbactam | 51 | 60.7 | 33 | 39.3 | 31 | 56.4 | 24 | 43.6 | – | – | – | – |
Piperacillin/tazobactam | 55 | 65.5 | 29 | 34.5 | 30 | 53.6 | 26 | 46.4 | 36 | 65.5 | 19 | 34.5 |
Amoxicillin-/clavulanic acid | – | – | – | – | – | – | – | – | 12 | 46.2 | 14 | 53.8 |
Cefpodoxime | – | – | – | – | – | – | – | – | 18 | 40.0 | 27 | 60.0 |
Cefuroxime | 37 | 46.3 | 43 | 53.8 | 23 | 45.1 | 28 | 54.9 | – | – | – | – |
Ceftriaxone | 21 | 26.3 | 59 | 73.8 | 16 | 27.6 | 42 | 72.4 | 22 | 38.6 | 35 | 61.4 |
Fosfomycin | – | – | – | – | – | – | – | – | 15 | 88.2 | 2 | 11.8 |
Levofloxacin | – | – | – | – | – | – | – | – | 32 | 59.3 | 22 | 40.7 |
Ciprofloxacin | – | – | – | – | – | – | – | – | 25 | 73.5 | 9 | 26.5 |
Meropenem | 54 | 73.0 | 20 | 27.0 | 34 | 64.2 | 19 | 35.8 | 31 | 83.8 | 6 | 16.2 |
Vancomycin | 63 | 74.1 | 22 | 25.9 | 40 | 70.2 | 17 | 29.8 | – | – | – | – |
Cotrimoxazole | – | – | – | – | – | – | – | – | 27 | 48.2 | 29 | 51.8 |
Nitrofurantoin | – | – | – | – | – | – | – | – | 10 | 100 | 0 | 0.0 |
Ampicillin/sulbactam/vancomycin | 76 | 90.5 | 8 | 9.5 | 49 | 89.1 | 6 | 10.9 | 27 | 96.4 | 1 | 3.6 |
Piperacillin/tazobactam/vancomycin | 79 | 94.0 | 5 | 6.0 | 48 | 85.7 | 8 | 14.3 | 26 | 100 | 0 | 0.0 |
Meropenem/vancomycin | 73 | 100 | 0 | 0.0 | 52 | 98.1 | 1 | 1.9 | 8 | 100 | 0 | 0.0 |
Ceftriaxone/vancomycin | 72 | 91.1 | 7 | 8.9 | 52 | 92.9 | 4 | 7.1 | 26 | 96.3 | 1 | 3.7 |